Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 4,560 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: assessment only control Clear all

Conditions: Respiratory Syncytial Virus Infections
Interventions: Suptavumab 30 mg/kg, Placebo Matched to Suptavumab, Suptavumab 30 mg/kg- 1 Dose, Suptavumab 30 mg/kg - 2 Doses; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: Up to 6 Months
Enrollment: 1,177 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 107
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 104 more

Conditions: Child Development
Interventions: Home visiting professional support model, Control; Behavioral · Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 4 Years to 5 Years
Enrollment: 302 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cancer, Physical Activity, Incentives
Interventions: Experimental, Control; Behavioral
Lead sponsor: California Polytechnic State University-San Luis Obispo; Other
Eligibility: 18 Years to 50 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Luis Obispo, California

Conditions: Bone Marrow Transplantation, Distress
Interventions: massage; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 5 Years to 18 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Malaria
Interventions: DM1157, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Rotator Cuff Tears, Rotator Cuff Injuries, Rotator Cuff Repair
Interventions: Cross-Education, Blood-Flow Restriction Training; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Physical Activity, Health-related Fitness, Cognition, Screen Time
Interventions: Exergaming intervention group, Traditional physical activity comparison; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 4 Years to 5 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Medication Adherence
Interventions: MESA; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 16 Years to 24 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 7
States / cities: Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more

Conditions: Renal Insufficiency, Chronic, Hyperkalemia
Interventions: Sodium Zirconium Cyclosilicate (SZC), Placebo, Lisinopril, Valsartan, Irbesartan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 42
States / cities: Surprise, Arizona • Tucson, Arizona • Canyon Country, California + 36 more

Conditions: Healthy Adult
Interventions: Niagen®; Dietary Supplement
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Infections, Respiratory Tract
Interventions: GSK1325756 Solution, GSK1325756 Solution Matching Placebo, GSK1325756 Tablet, GSK1325756 Tablet Matching Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: AZD5099, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy
Interventions: IVX-A12, Placebo; Biological
Lead sponsor: Icosavax, Inc.; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 264 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 10
States / cities: Tempe, Arizona • Hollywood, Florida • Stockbridge, Georgia + 7 more

Conditions: Uveitis
Interventions: Norflo Oro, Placebo for Norflo Oro; Drug
Lead sponsor: Eye Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Undefined
Interventions: MyMD1, Placebo; Drug
Lead sponsor: TNF Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: Diabetes Mellitus
Interventions: Muraglitazar; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 108
States / cities: Anniston, Alabama • Birmingham, Alabama • Haleyville, Alabama + 105 more

Conditions: Sphincter Ani Incontinence, Obstetric Trauma
Interventions: Physical Therapy (PT) and Behavioral Therapy (BT); Behavioral
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Underage Drinking
Interventions: eCHECKUP TO GO; Behavioral
Lead sponsor: Boise State University; Other
Eligibility: 16 Years to 18 Years
Enrollment: 311 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boise, Idaho

Conditions: Healthy Volunteers
Interventions: LY3023703, Placebo, Celecoxib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Cancer, Dermatologic Conditions
Interventions: Quality of Life (QoL) Assessment; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 3 Years and older
Enrollment: 839 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 4
States / cities: Basking Ridge, New Jersey • East White Plains, New York • Hauppauge, New York + 1 more

Conditions: Immunologic Deficiency Syndromes
Interventions: GC5107; Biological
Lead sponsor: Green Cross Corporation; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 10
States / cities: Centennial, Colorado • North Palm Beach, Florida • Plymouth, Minnesota + 6 more

Conditions: Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Interventions: NS-018, Best Available Therapy; Drug
Lead sponsor: NS Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Worcester, Massachusetts • Houston, Texas

Conditions: Hereditary Angioedema
Interventions: STAR-0215 (SC), Placebo (SC), STAR-0215 (IV), Placebo (IV); Drug
Lead sponsor: Astria Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Systemic Lupus Erythematosus
Interventions: AMG 557, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 12
States / cities: Anniston, Alabama • Phoenix, Arizona • Los Angeles, California + 7 more

Search by objective public record fields.

Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

The MOM Program: 5 Year Follow-up Study of a Home Visiting Program at The Children's Hospital of Philadelphia

Evaluating Whether Charity Incentives Motive Cancer Survivors to Increase Physical Activity

Massage for Pediatric Oncology

Safety and Pharmacokinetics Study of DM1157 to Treat Malaria

The Effect of Cross-Education on Shoulder Arthroscopy

Home-Based Exergaming Intervention

Motivational Enhancement System for Adherence (MESA) for Youth Starting ART

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

Nicotinamide Riboside, Vit B3 Analogue, and Brain Energy Metabolism

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects

Clinical Study Assessing the Safety, Tolerability, and Pharmacokinetics of Intravenous AZD5099 in Healthy Subjects

A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age

Assessment of the Anti-inflammatory Effects of Norflo Oro in Acute Relapses of HLA-B27 Associated Autoimmune Uveitis

Single Ascending-dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male Adult Subjects

PPAR - Combination With Metformin

Physical Therapy for Women With Obstetric Trauma and Anal Incontinence

Efficacy of a Web-Based Alcohol Intervention for High School Students

A Single Dose Study of LY3023703 in Healthy Participants

Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments

Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

A Study of STAR-0215 in Healthy Adult Participants

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus